Bangavax
Vaccine candidate against COVID-19 / From Wikipedia, the free encyclopedia
Bangavax, also known as Bancovid, is a COVID-19 vaccine candidate developed by a Bangladeshi pharmaceutical company Globe Biotech Limited.[1][2][3][4][5][6] The vaccine was initially called Bancovid.[7] On 23 November 2021, Globe Biotech has received ethical authorization from the Bangladesh Medical Research Council to conduct the first human trial.[8][9]
Quick Facts Vaccine description, Target ...
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | mRNA |
Clinical data | |
Other names | Bancovid |
Routes of administration | Intramuscular |
ATC code |
|
Close